Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction

Purpose: The rising prevalence of heart failure (HF) in midlife years in Indians is posing an economic challenge. Sacubitril/valsartan demonstrated a significant risk reduction of cardiovascular deaths by 20% and HF rehospitalizations by 21% versus enalapril but has a higher drug cost. High cost is...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sameer Bhaskar GOKHALE, Saumitra RAY, Vijay Kumar CHOPRA, Uday JADHAV, Gauri BILLA
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 2021-07-01
Ráidu:	Applied Medical Informatics
Fáttát:	enalapril costs and cost analysis (cca) heart failure medical economics sacubitril/valsartan
Liŋkkat:	https://ami.info.umfcluj.ro/index.php/AMI/article/view/811
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!